Skip to main content
Caplight Logo









Otitest

Otitest

Private
MatosinhosHealthcare & Life Scienceshttps://otitest.com

Last Round

Angel

Apr 27, 2026

Total Funding Raised

$59,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Otitest operates in Healthcare & Life Sciences and is based in Matosinhos. Its latest recorded funding round was an Angel round in April 2026.

Otitest is a healthtech company that develops a non-invasive, AI-powered pediatric otoscope device for home-based ear infection and fever detection.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Telemedicine

Business Model

B2C

Customer Profile

Hardware Sales, Subscription SaaS

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Otitest Comparables

Compare Otitest with similar companies based on industry and business-model similarity.

Otitest comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Remmie Health
84%
OtoNexus Medical Technologies Inc.
76%
Healthy Together
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Otitest Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AngelApr 27, 2026
CrowdfundingAug 20, 2025
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Raul Almeida

CEO & Founder

Founding Team

For institutional investors. Book with your work email.

Otitest Investors

Notable investors and investment history

Otitest investors
InvestorRounds
Angels WayAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    $59K raised from Angels Way.

  • Aug 20, 2025

    $250K raised in a crowdfunding round.

Book a demo to see all signals

For institutional investors. Book with your work email.

Otitest Filings

Explore SEC and related filing metadata, where available.

Otitest filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Otitest's valuation, stock price, and market status.

Is Otitest a public or private company?

Otitest is a private company.

What is the current stock price of Otitest?

Otitest is a private company, so its shares have no public market price. Caplight tracks Otitest's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Otitest worth (valuation)?

Valuation information for Otitest is not publicly available.

Can I buy Otitest stock?

Otitest shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Otitest's last funding round?

Otitest's most recent funding round was Angel on April 27, 2026.

Who are the main investors in Otitest?

Key investors in Otitest include Angels Way.

Will Otitest IPO soon?

No public IPO plans have been announced for Otitest.

How can I track Otitest secondary market activity?

Caplight tracks bids, offers, and trades in Otitest's shares on secondary markets.

Firmographic Details

HeadquartersMatosinhos
Employee Range4
Year Founded2017
Last FundingApr 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?